These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 25546187)

  • 1. The performance of contrast-enhanced FDG PET/CT for the differential diagnosis of unexpected ovarian mass lesions in patients with nongynecologic cancer.
    Lee JW; Lee JH; Cho A; Yun M; Lee JD; Kim YT; Kang WJ
    Clin Nucl Med; 2015 Feb; 40(2):97-102. PubMed ID: 25546187
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnostic accuracy of (18)F-FDG PET/CT compared with that of contrast-enhanced MRI of the breast at 3 T.
    Magometschnigg HF; Baltzer PA; Fueger B; Helbich TH; Karanikas G; Dubsky P; Rudas M; Weber M; Pinker K
    Eur J Nucl Med Mol Imaging; 2015 Oct; 42(11):1656-1665. PubMed ID: 26121928
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of combination of contrast-enhanced magnetic resonance imaging and positron emission tomography/computed tomography for evaluation of ovarian masses.
    Tsuboyama T; Tatsumi M; Onishi H; Nakamoto A; Kim T; Hori M; Sakane M; Hori Y; Morii E; Hatazawa J; Tomiyama N
    Invest Radiol; 2014 Aug; 49(8):524-31. PubMed ID: 24637584
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical significance of
    Zhang Y; Han J; Li J; Cao J; Zhou Y; Deng S; Zhang B; Yang Y
    J Cancer Res Clin Oncol; 2024 May; 150(5):265. PubMed ID: 38769201
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical impact of fluorodeoxyglucose-positron emission tomography scan/computed tomography in comparison with computed tomography on the detection of colorectal cancer recurrence.
    Deleau C; Buecher B; Rousseau C; Kraeber-Bodéré F; Flamant M; des Varannes SB; Frampas E; Galmiche JP; Matysiak-Budnik T
    Eur J Gastroenterol Hepatol; 2011 Mar; 23(3):275-81. PubMed ID: 21304319
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic accuracy of dual-time-point 18F-FDG PET/CT for the detection of axillary lymph node metastases in breast cancer patients.
    Hahn S; Hecktor J; Grabellus F; Hartung V; Pöppel T; Kimmig R; Forsting M; Antoch G; Heusner TA
    Acta Radiol; 2012 Jun; 53(5):518-23. PubMed ID: 22547387
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FDG-PET/CT in advanced ovarian cancer staging: value and pitfalls in detecting lesions in different abdominal and pelvic quadrants compared with laparoscopy.
    De Iaco P; Musto A; Orazi L; Zamagni C; Rosati M; Allegri V; Cacciari N; Al-Nahhas A; Rubello D; Venturoli S; Fanti S
    Eur J Radiol; 2011 Nov; 80(2):e98-103. PubMed ID: 20688446
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in the characterization of pancreatic masses: experience from tropics.
    Santhosh S; Mittal BR; Bhasin D; Srinivasan R; Rana S; Das A; Nada R; Bhattacharya A; Gupta R; Kapoor R
    J Gastroenterol Hepatol; 2013 Feb; 28(2):255-61. PubMed ID: 23278193
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic accuracy of 18F-FDG PET/CT in characterizing ovarian lesions and staging ovarian cancer: correlation with transvaginal ultrasonography, computed tomography, and histology.
    Castellucci P; Perrone AM; Picchio M; Ghi T; Farsad M; Nanni C; Messa C; Meriggiola MC; Pelusi G; Al-Nahhas A; Rubello D; Fazio F; Fanti S
    Nucl Med Commun; 2007 Aug; 28(8):589-95. PubMed ID: 17625380
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic performance of ¹⁸F-fluorothymidine PET/CT for primary colorectal cancer and its lymph node metastasis: comparison with ¹⁸F-fluorodeoxyglucose PET/CT.
    Nakajo M; Nakajo M; Kajiya Y; Jinguji M; Nishimata N; Shimaoka S; Nihara T; Aridome K; Tanaka S; Fukukura Y; Tani A; Koriyama C
    Eur J Nucl Med Mol Imaging; 2013 Aug; 40(8):1223-32. PubMed ID: 23653240
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of positron emission tomography/computed tomography in the management of patients with epithelial ovarian carcinoma after treatment.
    Nasu K; Abe W; Takai N; Tomonari K; Narahara H
    Arch Gynecol Obstet; 2011 May; 283(5):1121-6. PubMed ID: 20574659
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of 18F-FDG PET/CT in diagnosing peritoneal carcinomatosis in the restaging of patient with ovarian cancer as compared to contrast enhanced CT and tumor marker Ca-125.
    Rubini G; Altini C; Notaristefano A; Merenda N; Rubini D; Ianora AA; Asabella AN
    Rev Esp Med Nucl Imagen Mol; 2014; 33(1):22-7. PubMed ID: 23948509
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnosis of metastases from postoperative differentiated thyroid cancer: comparison between FDG and FLT PET/CT studies.
    Nakajo M; Nakajo M; Jinguji M; Tani A; Kajiya Y; Tanabe H; Fukukura Y; Nakabeppu Y; Koriyama C
    Radiology; 2013 Jun; 267(3):891-901. PubMed ID: 23468571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of fluorodeoxyglucose-positron emission tomography/computed tomography in differentiating between benign and malignant adrenal lesions.
    Ozcan Kara P; Kara T; Kara Gedik G; Kara F; Sahin O; Ceylan Gunay E; Sari O
    Nucl Med Commun; 2011 Feb; 32(2):106-12. PubMed ID: 21085046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of FDG-PET/CT in ovarian cancer patients with high tumor markers or suspicious lesion on contrast-enhanced CT in evaluation of recurrence and/or in determination of intraabdominal metastases.
    Sari O; Kaya B; Kara PO; Gedik GK; Celik C; Ozbek O; Serdengecti M
    Rev Esp Med Nucl Imagen Mol; 2012; 31(1):3-8. PubMed ID: 21549452
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Accuracy of FDG-PET/CT for Detection of Incidental Pre-Malignant and Malignant Colonic Lesions - Correlation with Colonoscopic and Histopathologic Findings.
    Kunawudhi A; Wong AK; Alkasab TK; Mahmood U
    Asian Pac J Cancer Prev; 2016; 17(8):4143-7. PubMed ID: 27644675
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Value of dual-time-point (18)F-fluorodeoxyglucose integrated positron emission and computed tomography in differentiation of malignant from benign gastrointestinal diseases].
    Xu XX; Cheng J; Xu WG; Dai D; Song XY; Ma WC; Zhu L; Zhu X
    Zhonghua Zhong Liu Za Zhi; 2012 May; 34(5):364-8. PubMed ID: 22883458
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Evaluation of positron emission tomography by using F-18-fluorodeoxyglucose in diagnosis of recurrent colorectal cancer].
    Kula Z; Szefer J; Zuchora Z; Romanowicz G; Pietrzak T
    Pol Merkur Lekarski; 2004; 17 Suppl 1():63-6. PubMed ID: 15603351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of incidental focal hypermetabolic uptake in the breast as detected by 18F-FDG PET/CT: clinical significance and differential diagnosis.
    Chae EY; Cha JH; Kim HH; Shin HJ; Kim HJ; Oh HY; Koh YH; Moon DH
    Acta Radiol; 2012 Jun; 53(5):530-5. PubMed ID: 22593124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of 18F-FDG PET/CT in detecting colorectal cancer recurrence in patients with elevated CEA levels.
    Ozkan E; Soydal C; Araz M; Kir KM; Ibis E
    Nucl Med Commun; 2012 Apr; 33(4):395-402. PubMed ID: 22367859
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.